PCSK9 inhibition tied to decreased psoriasis risk
20 Mar 2023
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.
Long-term OLE boosts potential of remibrutinib for CSU
20 Mar 2023
In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).
Indications/Uses : Symptoms related to venolymphatic insufficiency (heavy legs, pain, restless legs syndrome at bedtime). Functional symptoms related to acute hemorrhoidal attack.
Indications/Uses : Add-on therapy for the symptomatic treatment of adults w/ stable angina pectoris who are inadequately controlled by or intolerant to 1st-line antianginal therapies.
Sign Out
